Head-To-Head Contrast: ProKidney (NASDAQ:PROK) versus Jaguar Animal Health (NASDAQ:JAGX)

ProKidney (NASDAQ:PROK) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 2.1% of Jaguar Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

ProKidney has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.

Profitability

This table compares ProKidney and Jaguar Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Jaguar Animal Health	-169.04%	-1,194.94%	-115.55%

Valuation & Earnings

This table compares ProKidney and Jaguar Animal Health”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890,000.00	593.66	-$68.99 million	($0.53)	-3.30
Jaguar Animal Health	$11.51 million	0.09	-$53.43 million	($1,162.24)	0.00

Jaguar Animal Health has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ProKidney and Jaguar Animal Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2	1	4	1	2.50
Jaguar Animal Health	1	0	0	0	1.00

ProKidney currently has a consensus target price of $7.40, indicating a potential upside of 322.86%. Given ProKidney’s stronger consensus rating and higher probable upside, analysts clearly believe ProKidney is more favorable than Jaguar Animal Health.

Summary

ProKidney beats Jaguar Animal Health on 11 of the 15 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.